Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data
|
The expanded approval of Biktarvy was based on the Phase I
trial data showing efficacy in pregnant HIV-positive individuals. |
Study highlights importance of early interventions to combat HIV
A study has compared the development of HIV reservoirs—locations in the body where the virus persists in a latent state—between patients who ... View article...